Based on these observations, it is likely that the A 2A receptor agonist-induced reduction of D 2 receptor affinity, mainly involving the high-affinity state, is caused by an activation of the A 2A receptor in the heteromeric receptor complex causing a conformational change in the binding pocket of the D 2 receptor.
The A 2A /D 2 heteromeric receptor complex. Evidence has accumulated that intramembrane antagonistic receptor-receptor interactions between adenosine A 2A and dopamine D 2 receptors exist in dorsal and especially in the ventral striatum as studied in biochemical and receptor autoradiographic experiments. [1] [2] [3] [4] Both receptors are located on the dendritic spines of the striatopallidal GABA neurons. 5, 6 In 2002, it became possible to demonstrate the existence of A 2A /D 2 heteromeric receptor complexes in membrane preparations from human D 2 receptor (long-form) stably transfected SH-SY5Y neuroblastoma cells and from mouse fibroblast Ltk Ϫ cells stably transfected with human D 2 (long-form) receptors and transiently cotransfected with the A 2A receptor double tagged with hemagglutinin. 7 It was observed that the A 2A /D 2 heteromeric receptor complexes existed in the absence of exogenous A 2A and D 2 receptor agonists and therefore represented constitutive heteromers. Experiments using bioluminescence resonance energy transfer (BRET) and fluorescence resonance energy transfer (FRET) techniques indicate that the A 2A /D 2 heteromeric receptor complex represents a heterodimer (Canals et al., unpublished observations).
Based on these observations, it is likely that the A 2A receptor agonist-induced reduction of D 2 receptor affinity, mainly involving the high-affinity state, is caused by an activation of the A 2A receptor in the heteromeric receptor complex causing a conformational change in the binding pocket of the D 2 receptor. 8 A 2A receptor activation also leads to a reduction of the G-protein coupling of the D 2 receptor as seen from an antagonism of the GTP-induced crossregulation of the D 2 receptor with a disappearance of the high-affinity state. 9 These events result in a reduction of D 2 receptor signaling as inferred from the ability of A 2A receptor agonists to counteract the reduction of adenylyl cyclase activity 7 and the changes in intracellular Ca 2ϩ levels 8, 10 induced by D 2 receptors. Conversely, D 2 receptor activation antagonizes A 2A receptor signaling by a G i -mediated inhibition of the A 2A /G olf -activated adenylyl cyclase, which seems to be particularly pronounced in the dorsal striatum. 11 The existence of the A 2A /D 2 heteromeric receptor complex is probably also the molecular mechanism underlying the demonstrated coaggregation, cointernalization, and codesensitization of A 2A and D 2 receptors on A 2A or D 2 receptor agonist treatments. 7 1, 3 This may permit the reduction of the L-dopa dose and thus reduces the development of the L-dopa-induced dyskinesias related to a change in the phenotypic character of striatal GABAergic neurons with overexpression of prodynorphin and glutamic acid decarboxylase (GAD) mRNA levels 12 (see Chen et al., page S74). Carta et al. 13 (see Carta et al., page S39) have shown that combined treatment with an A 2A receptor antagonist and a low dose of L-dopa did not produce the possibly deleterious long-term increases in GAD, dynorphin, and enkephalin mRNA levels. By contrast, repeated treatment with a higher dose of L-dopa alone (which produced the same acute motor stimulant effect as did the combination of L-dopa plus A 2A antagonist) led to a significant increase in striatal GAD, dynorphin, and enkephalin expression. This absence of striatal gene inductions with repeated L-dopa plus A 2A antagonist was correlated with a stable turning response, in contrast to the sensitized turning response that developed after repeated treatment with L-dopa alone in this hemiparkinsonian model in rats. 13 It is of note that A 2A receptor antagonists alone produce antiparkinsonian effects without dyskinesias in parkinsonian monkeys. [14] [15] [16] It has also been indicated that longterm L-dopa therapy requires A 2A receptors for persistent behavioral sensitization as studied in A 2A receptor knockout mice. 17 The loss of inhibition of A 2A receptor signaling by the reduced D 2 receptor signaling in patients with Parkinson's disease (PD) adds to the parkinsonian symptoms, and thus antiparkinsonian actions of A 2A receptor antagonists can be related not only to an enhancement of D 2 receptor signaling but also to the blockade of increased A 2A receptor signaling of the hypodopaminergic state. 11, 18 A 2A receptor antagonists can counteract motor inhibitory and cataleptic effects after genetic and pharmacologic disruptions of D 2 receptor-mediated transmission. 19, 20 Data on A 2A /D 2 receptor cotrafficking 7 suggest that increased A 2A /D 2 receptor cointernalization in response to long-term L-dopa therapy, in combination with increased striatal adenosine tone, 7 may contribute to the deterioration of the therapeutic action of L-dopa. Simply stated, the desensitization may result from a decreased membrane presence of the D 2 receptor.
There is also the possibility that A 2A receptor antagonists can show neuroprotective activity because a higher coffee and caffeine intake was associated with reduced risk for PD. 21 7 Therefore, the relative amount of D 2 receptors in the two forms may be of importance in controlling the manifold aspects (efficacy and potency of D 2 signaling trafficking, sensitization, and desensitization) of the neuronal response to longterm L-dopa therapy.
The A 2A /mGluR5 heteromeric receptor complex. Our interest in A 2A /mGluR5 receptor interactions started with the demonstration that A 2A and group I mGluR receptor agonists could synergistically reduce affinity of D 2 receptor in striatal membranes. 25 Recently it has been possible to show the existence of heteromeric receptor complexes between A 2A receptors and the group I mGluR receptor subtype mGluR5 in coimmunoprecipitation experiments in HEK-293 cells cotransfected with Flag-A 2A and hemagglutinin mGluR5 receptors and in rat striatal membrane preparations involving native A 2A and mGluR5 receptors. 26 In contrast, there was a lack of coimmunoprecipitation between mGluR5 and mGluR1␤ (an isoform of another group I mGluR receptor) receptors. In agreement, it was found that the A 2A and mGluR5 receptors were colocalized on the membrane surface of cotransfected HEK-293 cells as shown with confocal laser microscopy after transient cotransfections. Furthermore, in preliminary fluorescence microscopy experiments with optical sectioning techniques (using the exhaustive photon reassignment process) we have found evidence for a strong A 2A /mGluR5 receptor colocalization in rat striatal primary cultures ( figure) . The detailed quantitative analysis of these results is in preparation (only the images corresponding to the pictures in the figure have been analyzed). It is presently unknown if adapter proteins, such as Homer proteins or the Shank family of scaffold proteins, link mGluR5 and A 2A receptors together in the het-eromeric receptor complex. The Homer proteins can bind to the C-terminal part of mGluR5 receptor and produce their clustering, and the Shank proteins link together the mGluR5 with the NMDA receptors. The A 2A /mGluR5 receptor heteromer was also present in the absence of exogenous agonists and appeared to be preformed, like the A 2A /D 2 receptor heteromer.
In the HEK-293 cells, it was possible to give a functional correlate to the A 2A /mGluR5 heteromeric receptor complex. 26 Therefore, A 2A /mGluR5 receptor coactivation produced a synergistic interaction at the level of extracellular signal-regulated kinase 1/2 (ERK) phosphorylation and c-fos expression. These and other results suggested that the A 2A /mGluR5 heteromeric receptor complex is involved in striatal neuron plasticity, including long-term potentiation and depression. 26 This synergism may be brought about by independent signals interacting at the level of the mitogen-activated protein kinase (MAPK) cascade. 27 There is also the possibility that on coactivation of the heteromeric receptor complex, a multireceptor complex may be assembled with receptor tyrosine kinases or nonreceptor tyrosine kinase Src, leading to ERK activation. [28] [29] [30] [31] [32] Another possible mechanism involved in the synergism between A 2A and mGluR5 receptors could be the modulation of mGluR5 receptor desensitization, which has been demonstrated for NMDA/mGluR5 and group II mGluR/mGluR5 receptor interactions. 33, 34 In these cases, the modulation seems to depend on the activation of phosphatase 2B, which reverses the agonistinduced protein kinase C-mediated desensitization of mGluR5 receptors. 33, 34 However, this mechanism would imply synergistic interactions at the secondmessenger level (Ca 2ϩ mobilization), 33, 34 which could not be demonstrated in A 2A /mGluR5 receptorcotransfected HEK-293 cells. 26 A similar A 2A /mGluR5 receptor synergism could be demonstrated in the rat striatum for c-fos expression correlated with a synergistic A 2A /mGluR5-mediated counteraction of phencyclidine-induced motor activity. 26 It is well known that this motor activity depends on D 2 receptor activity and has so far been blocked only by a high degree of D 2 receptor blockade. Therefore, the results suggest that A 2A / mGluR5 receptor costimulation can override a strong D 2 receptor-mediated transmission at the behavioral level. Long-term, but not short-term, treatment with an mGluR5 receptor antagonist can reverse the akinetic deficit in a model of PD. 35 It seems possible that this can in part be caused by an internalization and downregulation of the A 2A /mGluR5 heteromeric re- 42 ).
ceptor complex removing the D 2 receptor from inhibition of its signaling. In addition, there may also exist an acute mGluR5 receptor antagonist-induced counteraction of D 2 receptor blockade with haloperidol as seen from reduced rigidity and catalepsy 36 that may in part be exerted at the network level (e.g., at the level of the subthalamic nigral glutamate system). 4. CHPG inhibited contralateral rotational behaviors induced by quinpirole, an effect potentiated by CGS21680. 38 5. The mGluR5 receptor agonist CHPG in the nucleus accumbens increased GABA release in the ventral pallidum, an action strongly potentiated by coperfusion with CGS21680. 39 6. Coperfusion with quinpirole counteracted the increases in ventral pallidal GABA levels by CGS21680 and CHPG. 39 These results are compatible with the existence of A 2A /D 2 /mGluR5 multimeric complexes that are important in regulation of the dorsal and ventral striatopallidal GABA neurons and are of high relevance for management of PD (dorsal system) and schizophrenia and drug dependence (ventral system).
